Form 483

Otsuka Pharmaceutical Development & Commercialization, Inc Form 483, 2017-05-19

FDA issued a Form 483 to Otsuka Pharmaceutical Development & Commercialization, Inc on 2017-05-19 with 8 public-safe observations.

483· Form 483 issuedMedical Devices & Rad Health8 observations

Otsuka Pharmaceutical Development & Commercialization, Inc · Rockville, United States · Issued May 19, 2017

Overview

  • 8 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

19 May 2017
21 CFR 820.100(a)

Lack of or inadequate procedures

Cited by James M Simpson

19 May 2017
21 CFR 820.100(a)

Lack of or inadequate procedures

Cited by James M Simpson

19 May 2017
21 CFR 820.22

Quality Audits - defined intervals

Cited by James M Simpson

19 May 2017
21 CFR 820.22

Quality Audits - defined intervals

Cited by James M Simpson

19 May 2017
21 CFR 820.30(f)

Design verification - output does not meet input requirement

Cited by James M Simpson

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 820.100(a)Cited across public-safe Form 483 observations2x
21 CFR 820.22Cited across public-safe Form 483 observations2x
21 CFR 820.30(f)Cited across public-safe Form 483 observations2x
21 CFR 820.30(g)Cited across public-safe Form 483 observations2x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 8 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere